MARKET

INVA

INVA

Innoviva
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.55
+0.06
+0.52%
Opening 09:41 04/02 EDT
OPEN
11.43
PREV CLOSE
11.49
HIGH
11.65
LOW
11.43
VOLUME
11.52K
TURNOVER
--
52 WEEK HIGH
15.35
52 WEEK LOW
7.58
MARKET CAP
1.17B
P/E (TTM)
8.33
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average INVA stock price target is 13.50 with a high estimate of 19.00 and a low estimate of 8.00.

EPS

INVA News

More
  • Innoviva Announces Change of Location of Annual Meeting of Stockholders to Be Held on April 24, 2020
  • Business Wire · 1d ago
  • Armata Pharmaceuticals Announces Closing of Second Tranche of $25 Million Securities Purchase Agreement with Innoviva, Inc.
  • PR Newswire · 3d ago
  • Healthcare And Biotechnology Dashboard - Update
  • Seeking Alpha - Article · 03/24 18:33
  • How Does Innoviva's (NASDAQ:INVA) P/E Compare To Its Industry, After The Share Price Drop?
  • Simply Wall St. · 03/20 12:03

Industry

Pharmaceuticals
-0.30%
Pharmaceuticals & Medical Research
-0.08%

Hot Stocks

Symbol
Price
%Change

About INVA

Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.
More

Webull offers kinds of Innoviva Inc stock information, including NASDAQ:INVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INVA stock news, and many more online research tools to help you make informed decisions.